Mostrar el registro sencillo

dc.contributor.authorLechosa Muñiz, Carolina 
dc.contributor.authorPaz Zulueta, María 
dc.contributor.authorMendez-Legaza, Jose Manuel
dc.contributor.authorIrure Ventura, Juan
dc.contributor.authorCuesta González, Rocío
dc.contributor.authorCalvo Montes, Jorge
dc.contributor.authorLópez Hoyos, Marcos 
dc.contributor.authorLlorca Díaz, Francisco Javier 
dc.contributor.authorCabero Pérez, María Jesús 
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2022-02-01T17:23:15Z
dc.date.available2022-02-01T17:23:15Z
dc.date.issued2021
dc.identifier.issn1661-7827
dc.identifier.issn1660-4601
dc.identifier.urihttp://hdl.handle.net/10902/23824
dc.description.abstractBreastfeeding mothers were excluded from the clinical trials conducted for vaccines against SARS-CoV-2. Since the start of the vaccination, some doubts have arisen regarding its compatibility with breastfeeding. The aim of this study was to analyse the presence of anti-SARS-CoV-2 antibodies in breast milk and serum (IgG and IgA) of vaccinated breastfeeding women. The main variables of the observational study were: adverse related events after vaccination and determination of the presence of IgG and IgA isotypes antibodies in serum and in breast milk of vaccinated women against the SARS-CoV-2 antigens. Results: 110 breastfeeding mothers were included; 70 women (63.6%) were vaccinated with two doses of BNT162b2, 20 women (18.2%) with two doses of mRNA-1273, and 20 women (18.2%) with a single dose of ChAdOx1-S. Regarding adverse reactions and vaccine safety, 38 women had no adverse reactions; 20 (18.2%) had general malaise or adenopathies; 10 (9.1%) had a headache; and 7 (6.4%) had fever. When analysing IgG antibodies, significantly higher levels of antibodies were found in serum and breast milk from mothers vaccinated with BNT162b2 or mRNA-1273 vs. ChAdOx1-S (p < 0.001 and p = 0.001, respectively). Analysing IgA antibodies, significant differences were found when comparing mean values in serum from mothers vaccinated with BNT162b2 or mRNA-1273 vs. ChAdOx1-S (0.12, 0.16, and 0.02, respectively; p < 0.001) and breast milk of mothers vaccinated when comparing BNT16b2 vs. ChAdOx1-S. All vaccinated breastfeeding mothers had serum anti-S1 IgG antibodies in response to vaccination against SARS-CoV-2, regardless of the commercial vaccine administered. Conclusions: the anti-SARS-CoV-2 vaccines were well tolerated by the mothers and the breastfed infant. In addition, breastfeeding mothers offer their infants IgA and IgG isotype antibodies directed against SARS-CoV-2 protein S in breast milk.es_ES
dc.format.extent20 p.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rights© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.es_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceInt J Environ Res Public Health . 2021 Aug 21;18(16):8831es_ES
dc.subject.otherAntibodieses_ES
dc.subject.otherBreastfeedinges_ES
dc.subject.otherBreast Milkes_ES
dc.subject.otherCOVID-19 Vaccinees_ES
dc.subject.otherMaternal Immunityes_ES
dc.subject.otherNeonatal Immunityes_ES
dc.titleInduction of SARS-CoV-2-specific IgG and IgA in serum and milk with different SARS-CoV-2 vaccines in breastfeeding women: a cross-sectional study in northern Spaines_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.3390/ijerph18168831
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.Excepto si se señala otra cosa, la licencia del ítem se describe como © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.